Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 15/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | FASN | P49327 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14647140 | 0.82 | PARP1 (0.38) | PARP1 | |
| SCHEMBL31330117 | 0.75 | PARP1 (0.44) | PARP1CYP1A2 | |
| SCHEMBL14647112 | 0.73 | PARP1 (0.46) | PARP1CYP1A2 | |
| SCHEMBL15721658 | 0.72 | PARP1 (0.46) | PARP1CYP1A2 | |
| SCHEMBL29893389 | 0.70 | PARP1 (0.50) | PARP1CYP1A2 | |
| SCHEMBL15533169 | 0.69 | PARP1 (0.49) | PARP1CYP1A2 | |
| SCHEMBL14647181 | 0.69 | PARP1 (0.56) | PARP1 | |
| SCHEMBL14647194 | 0.69 | PARP1 (0.47) | PARP1CYP1A2 | |
| SCHEMBL29893199 | 0.69 | PARP1 (0.48) | PARP1CYP1A2 | |
| SCHEMBL14647128 | 0.68 | PARP1 (0.51) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119371425-A | Nitrogen-containing heterocyclic compound, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2025-01-28 | — | — | CN | disclosed |
| EP-4313308-A1 | TEAD INHIBITORS AND USES THEREOF | Cedilla Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230098872-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2022204452-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| EP-2733144-B1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO LTD (JP) | 2016-01-06 | — | — | EP | disclosed |
| US-9062061-B2 | Compound having PARP inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-9062061-B2 | Compound having PARP inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-9062061-B2 | Compound having PARP inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-20140243320-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20140243320-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20140243320-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
| EP-2733144-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2014-05-21 | — | — | EP | disclosed |
| EP-2733144-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2014-05-21 | — | — | EP | disclosed |
| WO-2013008872-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | 参天製薬株式会社 (JP) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230098872-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | PARP1 2475/4885CYP1A2 1435/4885FASN 3406/4885 |
| US-20140243320-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | PARP1, PARP11, PARP2 | PARP1 1/4885CYP1A2 3168/4885FASN 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.